Palisade Bio, Inc. (Nasdaq: PALI) a late-stage biopharma company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that it entered into an exclusive license with the Regents of the University of California, expanding its proprietary technology for detecting enzymatic protease activity in human clinical samples. Under the terms of this agreement, in combination with a related 2020 license from UC, the Company receives a worldwide exclusive license to patent rights covering certain engineered substrates and their use in measuring degradative enzymes for disease conditions, including cancer. This technology was originally developed in the laboratory of Dr. Michael Heller at University of California San Diego.

“Many chronic endocrine and inflammatory diseases are associated with chronic proteolytic enzyme leak from the GI tract. We have a deep understanding of the protease biology of the GI tract, and with the license we are expanding our proprietary whole-blood assay to identify the specific protease activity contributing to these diseases. As we expand our pipeline of drug products, these assets form a platform for novel target and drug discovery, as well as highly efficient patient selection and measurement of clinical response during drug development,” said Tom Hallam, Ph.D., CEO of Palisade Bio.

About Palisade Bio, Inc.

Palisade Bio is a late-stage biopharma company advancing therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio’s innovative lead asset, LB1148, is a Phase 3-ready protease inhibitor with the potential to both reduce abdominal adhesions and help restore bowel function following surgery. Positive data from of a Phase 2 trial of LB1148 demonstrated safety and tolerability as well as a statistically significant improvement in return to bowel function and decrease in length of stay in ICU and hospital compared to placebo. Palisade Bio believes that its investigational therapies have the potential to address the myriad health conditions and complications associated with chronic disruption of the gastrointestinal epithelial barrier. For more information, please go to www.palisadebio.com.

Forward Looking Statements

This communication contains “forward-looking” statements, including, without limitation, statements related to expectations regarding expansion of Palisade’s piepline, and other statements related to Palisade’s development programs. Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements are based upon Palisade’s current expectations. Forward-looking statements involve risks and uncertainties. Palisade’s actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, related to the Company’s ability to advance its preclinical programs and the uncertain and time-consuming regulatory approval process. Additional risks and uncertainties can be found in Palisade Bio’s (formerly known as Seneca Biopharma, Inc.) Quarterly Report on Form 10-Q for the quarter ended March 31, 2021. Palisade expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Palisade’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Palisade Bio Investor Relations Contact:
CORE IR
This email address is being protected from spambots. You need JavaScript enabled to view it.

Palisade Bio Media Relations Contact:
CORE IR
Jules Abraham
This email address is being protected from spambots. You need JavaScript enabled to view it.
917-885-73478

Source: Palisade Bio